PRKAA2 and cardiac hypertrophy: Genetic inhibition of AMPK aggravates cardiac hypertrophy and promotes HF progression, while overexpression or pharmacological activation of AMPK greatly attenuates development and progression of these conditions (Viollet et al., 2009; Feng et al., 2018).